首页> 美国卫生研究院文献>RMD Open >Original article: Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs

【2h】

Original article: Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs

机译：原始文章：Baricitinib对类风湿关节炎患者1年结构性关节损伤的影像学进展的影响以及对传统的合成疾病缓解类风湿药的反应不足

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundBaricitinib was efficacious in a 24-week phase III study in patients with rheumatoid arthritis (RA) and an inadequate response to conventional synthetic disease-modifying anti rheumatic drugs (DMARDs) (csDMARDs) (RA-BUILD).

机译：背景Baricitinib在类风湿关节炎（RA）且对常规合成抗风湿药（DMARDs）（csDMARDs）（RA-BUILD）反应不足的患者的24周III期研究中有效。

著录项

期刊名称 RMD Open
作者
Desirée van der Heijde; Maxime Dougados; Ying-Chou Chen; Maria Greenwald; Edit Drescher; Rena Klar; Li Xie; Inmaculada de la Torre; Terence P Rooney; Sarah L Witt; Douglas E Schlichting; Stephanie de Bono; Paul Emery;
展开▼
作者单位

展开▼
年(卷),期 2018(4),1
年度 2018
页码 e000662
总页数 7
原文格式 PDF
正文语种
中图分类
关键词
rheumatoid arthritis radiographic progression RA-BUILD baricitinib csDMARD;

机译：类风湿关节炎;影像学进展;RA-BUILD;baricitinib;csDMARD;

相似文献

外文文献
中文文献
专利

1. Original article: Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis [J] . Desirée van der Heijde, Michael Schiff, Yoshiya Tanaka, RMD Open . 2019,第1期

机译：原始文章：类风湿关节炎患者在接受Baricitinib治疗2年后，其结构性关节损伤的放射学进展率较低
2. Original article: Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs [J] . Vibeke Strand, Kurt de Vlam, Jose A Covarrubias-Cobos, RMD Open . 2019,第1期

机译：原始文章：Tofacitinib或阿达木单抗与安慰剂：OPAL病人加宽的患者报告结局-一项对传统合成疾病抗风湿药反应不足的活动性银屑病关节炎的III期研究
3. Original article: Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systemati [J] . Ernest Choy, Nick Freemantle, Clare Proudfoot, RMD Open . 2019,第1期

机译：原始文章：sarilumab联合疗法对类风湿性关节炎患者的疗效和安全性评估，这些患者对传统的改变疾病的抗风湿药或肿瘤坏死因子α抑制剂反应不足：系统性
4. Original article: Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis [O] . Desirée van der Heijde, Michael Schiff, Yoshiya Tanaka, 2019

机译：原始文章：类风湿关节炎患者在接受Baricitinib治疗2年后其结构性关节损伤的放射学进展率较低
5. Correction to: Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT [O] . Vibeke Strand, Janet Pope, Namita Tundia, 2020

机译：矫正：Upadacitinib在类风湿性关节炎患者中提高了患者报告的结果，对常规的合成疾病改性抗胃酸药物的反应不足：选择下一步的结果

Original article: Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs

摘要

著录项

相似文献

相关主题

期刊订阅